{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:25Z","timestamp":1786735765419,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jcrt.jcrt_137_17","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T07:20:25Z","timestamp":1540884025000},"page":"30","source":"Crossref","is-referenced-by-count":10,"title":["Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study"],"prefix":"10.4103","volume":"16","author":[{"given":"Kavyanjali","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopeshwar","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.244438-1","unstructured":"American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 2015."},{"key":"key-10.4103\/0973-1482.244438-2","first-page":"16","volume-title":"The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: An overview with emphasis on the myeloid neoplasms","author":"Vardiman","year":"2010","journal-title":"Chem Biol Interact"},{"key":"key-10.4103\/0973-1482.244438-3","first-page":"277","volume-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"key-10.4103\/0973-1482.244438-4","first-page":"154","volume-title":"Chronic myeloid leukemia data from India","author":"Bansal","year":"2013","journal-title":"Indian J Med Paediatr Oncol","ISSN":"https:\/\/id.crossref.org\/issn\/0971-5851","issn-type":"print"},{"key":"key-10.4103\/0973-1482.244438-5","first-page":"252","volume-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","author":"Jabbour","year":"2016","journal-title":"Am J Hematol"},{"key":"key-10.4103\/0973-1482.244438-6","first-page":"S141","volume-title":"A review of the European leukemiaNet recommendations for the management of CML","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0973-1482.244438-7","first-page":"4611","volume-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244438-8","first-page":"1018","volume-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0973-1482.244438-9","first-page":"1208","volume-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European leukemiaNet","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244438-10","first-page":"37","volume-title":"Cytokine profiling as a prognostic markers in chronic myeloid leukemia patients","author":"Singer","year":"2011","journal-title":"Egypt J Immunol"},{"key":"key-10.4103\/0973-1482.244438-11","first-page":"671","volume-title":"Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"key":"key-10.4103\/0973-1482.244438-12","first-page":"1263","volume-title":"TGF-\u03b1 and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy","author":"Nievergall","year":"2016","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.244438-13","first-page":"448","volume-title":"IL-6 as a keystone cytokine in health and disease","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"key-10.4103\/0973-1482.244438-14","doi-asserted-by":"crossref","unstructured":"Hirano T, Kishimoto T. Interleukin 6. In: Sporn MB, Roberts AB, editors. Peptide Growth Factors and Their Receptors. Heidelberg, Germany: Springer-Verlag; 1990. p. 634-4.","DOI":"10.1007\/978-3-642-49295-2_14"},{"key":"key-10.4103\/0973-1482.244438-15","first-page":"a016295","volume-title":"IL-6 in inflammation, immunity, and disease","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key-10.4103\/0973-1482.244438-16","first-page":"143","volume-title":"Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis","author":"Anand","year":"1998","journal-title":"Hematol Oncol"},{"key":"key-10.4103\/0973-1482.244438-17","first-page":"51","volume-title":"Molecular detection of survivin expression, antiapoptotic gene, and other prognostic markers, how they are correlated and how it could be of prognostic value in chronic myeloid leukemia patient","author":"Zhara","year":"2007","journal-title":"Egypt J Immunol"},{"key":"key-10.4103\/0973-1482.244438-18","first-page":"998","volume-title":"Identification of genes potentially involved in disease transformation of CML","author":"Janssen","year":"2005","journal-title":"Leukemia"},{"key":"key-10.4103\/0973-1482.244438-19","first-page":"255","volume-title":"Cytokines in cancer drug resistance: Cues to new therapeutic strategies","author":"Jones","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/0973-1482.244438-20","first-page":"879","volume-title":"IL-6 blocks a discrete early step in lymphopoiesis","author":"Maeda","year":"2005","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244438-21","first-page":"661","volume-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"key-10.4103\/0973-1482.244438-22","first-page":"40","volume-title":"Effect of STAT3 inhibitor in chronic myeloid leukemia associated signaling pathway: A mathematical modeling, simulation and systems biology study","author":"Kumar","year":"2016","journal-title":"Biotech"},{"key":"key-10.4103\/0973-1482.244438-23","first-page":"405","volume-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","author":"Chen","year":"2013","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:33:20Z","timestamp":1786732400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_137_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["244438"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_137_17","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}